CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
about
A perspective on the role of estrogen in hormone-induced prostate carcinogenesisCYP17 MspA1 Gene Polymorphism and Breast Cancer Patients According to Age of Onset in Cancer Institute of Iran.CYP17 polymorphisms and prostate cancer outcomes.Estrogen and progesterone-related gene variants and colorectal cancer risk in women.Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.Genetic variation: effect on prostate cancer.The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort.Hormones and prostate carcinogenesis: Androgens and estrogens.Estrogen metabolism and breast cancer.CYP17 T27C polymorphism and prostate cancer risk: a meta-analysis based on 31 studiesGenetic variation in CYP17A1 and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, CaliforniaPolymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancerCommon Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in womenGenetic susceptibility to cancer: the role of polymorphisms in candidate genes.Hormone-related pathways and risk of breast cancer subtypes in African American women.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Erectile dysfunction and the risk of prostate cancer.Quantitative assessment of the association between CYP17 rs743572 polymorphism and prostate cancer risk.CYP3A variation, premenopausal estrone levels, and breast cancer risk.Association between CYP17 T-34C rs743572 and breast cancer risk.Evaluation of Local CYP17A1 and CYP19A1 Expression Levels as Prognostic Factors in Postmenopausal Invasive Ductal Breast Cancer Cases.Menstrual and reproductive factors in women, genetic variation inCYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort
P2860
Q27004552-1EC0E614-4085-48FC-B2CC-9B820C4639FDQ33711108-5664BD13-1145-4B5A-ACC2-B68C7BA45D41Q33884273-A4A6AE0F-9269-45D0-A5EC-485F5006604DQ33917508-19EC7DA4-AFEE-43F5-A3AD-E322315CCB30Q33942587-98919FC4-B73C-4597-B8C3-59766F5EBB1BQ34099786-06263A40-845A-49C0-BFE2-EFD99B861793Q34663656-CA56A239-7FB9-454F-BAC0-DDC0A3EE1388Q34962430-DB437CF1-BBE1-47D1-BCD8-D7964E91A6F1Q35558999-53559B18-1EF5-4972-A4CD-DBADA9C7959CQ35687198-621AC9AC-1674-45B5-9D49-79907961F8EDQ35861660-C128AFEF-D6DF-4697-BB10-18DED2DDBB6CQ36681449-04F7F0BA-B4B9-49D9-BBDD-0491891207AEQ36763072-AF3BD9F1-AC37-4DE9-9F53-D68BA0E7C064Q37090417-CF216A30-147C-4FDF-A7E0-24C0C8C7BF58Q37134564-3C587A0B-918C-4AFF-87E1-91AE91904A45Q37148034-6E06BDC5-167E-4FA2-8EF5-866C79D96B66Q37174313-F18F2397-1FFC-4A21-B1AB-76BC31205E37Q37371491-5CFA8FBF-C05C-4643-A752-258B46E6C01DQ38620751-86E3186A-051D-43AC-B7D8-0806E3E796B7Q41592854-2CC3FDD9-43D5-419A-A477-BDFF9FA90206Q43845691-CDCA2323-48B1-4DEB-B40A-251F25C8CB3DQ44288178-56F5F257-631E-47EC-9707-CC98FEDA0CD4Q49163775-C5CE25ED-7C73-4A8C-B131-9CF58E518811Q51671074-93A68A0F-7338-49C5-ADC0-BB090ECDD7E5Q57026715-5A2B26F0-DD30-4199-8A7E-5E2735010C5E
P2860
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
CYP17 genetic variation and ri ...... ncer Cohort Consortium (BPC3).
@en
CYP17 genetic variation and ri ...... state Cancer Cohort Consortium
@nl
type
label
CYP17 genetic variation and ri ...... ncer Cohort Consortium (BPC3).
@en
CYP17 genetic variation and ri ...... state Cancer Cohort Consortium
@nl
prefLabel
CYP17 genetic variation and ri ...... ncer Cohort Consortium (BPC3).
@en
CYP17 genetic variation and ri ...... state Cancer Cohort Consortium
@nl
P2093
P50
P1476
CYP17 genetic variation and ri ...... ncer Cohort Consortium (BPC3).
@en
P2093
Daniel O Stram
Eugenia E Calle
Fredrick R Schumacher
Göran Berglund
J Michael Gaziano
Joel Hirschhorn
Laurence N Kolonel
Malcolm C Pike
Michael J Thun
P304
P356
10.1158/1055-9965.EPI-07-0589
P50
P577
2007-11-01T00:00:00Z